. Author manuscript; available in PMC: 2017 Aug 1.

Published in final edited form as: Arthritis Rheumatol. 2016 Aug;68(8):1818–1827. doi: 10.1002/art.39647

Table 4.

Propensity-adjusted changes in body mass index (BMI) at 6 months compared to methotrexate and considering concurrent medication use.

	Unadjusted	Matched Weighting (Propensity-Adjusted)

			Excluding Concurrent MTX
				Compared to MTX Alone
Prednisone (N=37,641)	0.075^*** (0.042, 0.11	0.17 ^*** (0.13, 0.20)	0.16 ^*** (0.12, 0.20)	0.16 ^*** (0.12, 0.20)
Leflunomide (N=22,257)	−0.47 ^*** (−0.53, −0.42)	−0.43^*** (−0.49, −0.37)	−0.42 ^*** (−0.49, −0.35)	−0.42 ^*** (−0.49, −0.35)
TNFi (N=27,337)	0.024 (−0.018, 0.067)	0.025 (−0.019, 0.070)	−0.016 (−0.070, 0.038)	−0.016 (−0.070, 0.037)

p<0.05,

^**

p<0.01,

^***

p<0.001